ETN
57
-23
BRK.B
52
2
CTSH
45
-12
APH
65
-3
KMX
58
4
STZ
52
9
EFX
66
-14
EQIX
58
-11
PG
64
-2
ABT
63
-2
ECL
42
-28
MDT
57
-3
INTC
45
-2
LEN
19
-2
HAS
46
-2
EL
30
-18
GLW
53
-2
TSCO
46
-4
FTI
78
4
EQT
54
-11
ETN
57
-23
BRK.B
52
2
CTSH
45
-12
APH
65
-3
KMX
58
4
STZ
52
9
EFX
66
-14
EQIX
58
-11
PG
64
-2
ABT
63
-2
ECL
42
-28
MDT
57
-3
INTC
45
-2
LEN
19
-2
HAS
46
-2
EL
30
-18
GLW
53
-2
TSCO
46
-4
FTI
78
4
EQT
54
-11
Financhill
Back

Apellis Pharmaceuticals 10K Form

Sell
33

APLS
Apellis Pharmaceuticals

Last Price:
$24.16
Seasonality Move:
7.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $781.4M
Cash Flow: $19.3M
Price / Cash Flow: 0
Annual Sales: $1.84
Price / Book: 13.26

Profitability

EPS (TTM): -1.59000
Net Income (TTM): $-197.9M
Gross Margin: $663.6M
Return on Equity: -83.06%
Return on Assets: -22.95%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 7 years for APLS is 84.93%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 64.13% of Gross Profit Margin.
  • The Research & Development expenses have been 41.92% of Revenue.
  • The Net Earning history of APLS is -25.32% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 1.98
Current Ratio: 4.25
Quick Ratio: 3.68

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 1222.17

APLS Technical Analysis vs Fundamental Analysis

Sell
33
Apellis Pharmaceuticals (APLS) is a Sell

Is Apellis Pharmaceuticals a Buy or a Sell?